Advertisement

Topics

Why Teva's Stock Could Crash Another 50%

19:00 EST 7 Nov 2017 | BioSpace

Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.

Original Article: Why Teva's Stock Could Crash Another 50%

NEXT ARTICLE

More From BioPortfolio on "Why Teva's Stock Could Crash Another 50%"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...